Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action

Jiekun Xuan, Guihua Pan, Yunping Qiu, Lun Yang, Mingming Su, Yumin Liu, Jian Chen, Guoyin Feng, Yiru Fang, Wei Jia, Qinghe Xing, Lin He

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Despite recent advances in understanding the pathophysiology of schizophrenia and the mechanisms of antipsychotic drug action, the development of biomarkers for diagnosis and therapeutic monitoring in schizophrenia remains challenging. Metabolomics provides a powerful approach to discover diagnostic and therapeutic biomarkers by analyzing global changes in an individual's metabolic profile in response to pathophysiological stimuli or drug intervention. In this study, we performed gas chromatography-mass spectrometry based metabolomic profiling in serum of unmedicated schizophrenic patients before and after an 8-week risperidone monotherapy, to detect potential biomarkers associated with schizophrenia and risperidone treatment. Twenty-two marker metabolites contributing to the complete separation of schizophrenic patients from matched healthy controls were identified, with citrate, palmitic acid, myo-inositol, and allantoin exhibiting the best combined classification performance. Twenty marker metabolites contributing to the complete separation between posttreatment and pretreatment patients were identified, with myo-inositol, uric acid, and tryptophan showing the maximum combined classification performance. Metabolic pathways including energy metabolism, antioxidant defense systems, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabolism were found to be disturbed in schizophrenic patients and partially normalized following risperidone therapy. Further study of these metabolites may facilitate the development of noninvasive biomarkers and more efficient therapeutic strategies for schizophrenia.

Original languageEnglish (US)
Pages (from-to)5433-5443
Number of pages11
JournalJournal of Proteome Research
Volume10
Issue number12
DOIs
StatePublished - Dec 2 2011
Externally publishedYes

Fingerprint

Metabolomics
Risperidone
Biomarkers
Schizophrenia
Metabolites
Inositol
Serum
Metabolism
Allantoin
Palmitic Acid
Biosynthesis
Therapeutics
Uric Acid
Citric Acid
Tryptophan
Gas chromatography
Metabolome
Antipsychotic Agents
Mass spectrometry
Neurotransmitter Agents

Keywords

  • atypical antipsychotics
  • gas chromatography-mass spectrometry
  • metabolomics
  • potential biomarkers
  • schizophrenia

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. / Xuan, Jiekun; Pan, Guihua; Qiu, Yunping; Yang, Lun; Su, Mingming; Liu, Yumin; Chen, Jian; Feng, Guoyin; Fang, Yiru; Jia, Wei; Xing, Qinghe; He, Lin.

In: Journal of Proteome Research, Vol. 10, No. 12, 02.12.2011, p. 5433-5443.

Research output: Contribution to journalArticle

Xuan, J, Pan, G, Qiu, Y, Yang, L, Su, M, Liu, Y, Chen, J, Feng, G, Fang, Y, Jia, W, Xing, Q & He, L 2011, 'Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action', Journal of Proteome Research, vol. 10, no. 12, pp. 5433-5443. https://doi.org/10.1021/pr2006796
Xuan, Jiekun ; Pan, Guihua ; Qiu, Yunping ; Yang, Lun ; Su, Mingming ; Liu, Yumin ; Chen, Jian ; Feng, Guoyin ; Fang, Yiru ; Jia, Wei ; Xing, Qinghe ; He, Lin. / Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. In: Journal of Proteome Research. 2011 ; Vol. 10, No. 12. pp. 5433-5443.
@article{c90e913ef611446794a21406689ead81,
title = "Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action",
abstract = "Despite recent advances in understanding the pathophysiology of schizophrenia and the mechanisms of antipsychotic drug action, the development of biomarkers for diagnosis and therapeutic monitoring in schizophrenia remains challenging. Metabolomics provides a powerful approach to discover diagnostic and therapeutic biomarkers by analyzing global changes in an individual's metabolic profile in response to pathophysiological stimuli or drug intervention. In this study, we performed gas chromatography-mass spectrometry based metabolomic profiling in serum of unmedicated schizophrenic patients before and after an 8-week risperidone monotherapy, to detect potential biomarkers associated with schizophrenia and risperidone treatment. Twenty-two marker metabolites contributing to the complete separation of schizophrenic patients from matched healthy controls were identified, with citrate, palmitic acid, myo-inositol, and allantoin exhibiting the best combined classification performance. Twenty marker metabolites contributing to the complete separation between posttreatment and pretreatment patients were identified, with myo-inositol, uric acid, and tryptophan showing the maximum combined classification performance. Metabolic pathways including energy metabolism, antioxidant defense systems, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabolism were found to be disturbed in schizophrenic patients and partially normalized following risperidone therapy. Further study of these metabolites may facilitate the development of noninvasive biomarkers and more efficient therapeutic strategies for schizophrenia.",
keywords = "atypical antipsychotics, gas chromatography-mass spectrometry, metabolomics, potential biomarkers, schizophrenia",
author = "Jiekun Xuan and Guihua Pan and Yunping Qiu and Lun Yang and Mingming Su and Yumin Liu and Jian Chen and Guoyin Feng and Yiru Fang and Wei Jia and Qinghe Xing and Lin He",
year = "2011",
month = "12",
day = "2",
doi = "10.1021/pr2006796",
language = "English (US)",
volume = "10",
pages = "5433--5443",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action

AU - Xuan, Jiekun

AU - Pan, Guihua

AU - Qiu, Yunping

AU - Yang, Lun

AU - Su, Mingming

AU - Liu, Yumin

AU - Chen, Jian

AU - Feng, Guoyin

AU - Fang, Yiru

AU - Jia, Wei

AU - Xing, Qinghe

AU - He, Lin

PY - 2011/12/2

Y1 - 2011/12/2

N2 - Despite recent advances in understanding the pathophysiology of schizophrenia and the mechanisms of antipsychotic drug action, the development of biomarkers for diagnosis and therapeutic monitoring in schizophrenia remains challenging. Metabolomics provides a powerful approach to discover diagnostic and therapeutic biomarkers by analyzing global changes in an individual's metabolic profile in response to pathophysiological stimuli or drug intervention. In this study, we performed gas chromatography-mass spectrometry based metabolomic profiling in serum of unmedicated schizophrenic patients before and after an 8-week risperidone monotherapy, to detect potential biomarkers associated with schizophrenia and risperidone treatment. Twenty-two marker metabolites contributing to the complete separation of schizophrenic patients from matched healthy controls were identified, with citrate, palmitic acid, myo-inositol, and allantoin exhibiting the best combined classification performance. Twenty marker metabolites contributing to the complete separation between posttreatment and pretreatment patients were identified, with myo-inositol, uric acid, and tryptophan showing the maximum combined classification performance. Metabolic pathways including energy metabolism, antioxidant defense systems, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabolism were found to be disturbed in schizophrenic patients and partially normalized following risperidone therapy. Further study of these metabolites may facilitate the development of noninvasive biomarkers and more efficient therapeutic strategies for schizophrenia.

AB - Despite recent advances in understanding the pathophysiology of schizophrenia and the mechanisms of antipsychotic drug action, the development of biomarkers for diagnosis and therapeutic monitoring in schizophrenia remains challenging. Metabolomics provides a powerful approach to discover diagnostic and therapeutic biomarkers by analyzing global changes in an individual's metabolic profile in response to pathophysiological stimuli or drug intervention. In this study, we performed gas chromatography-mass spectrometry based metabolomic profiling in serum of unmedicated schizophrenic patients before and after an 8-week risperidone monotherapy, to detect potential biomarkers associated with schizophrenia and risperidone treatment. Twenty-two marker metabolites contributing to the complete separation of schizophrenic patients from matched healthy controls were identified, with citrate, palmitic acid, myo-inositol, and allantoin exhibiting the best combined classification performance. Twenty marker metabolites contributing to the complete separation between posttreatment and pretreatment patients were identified, with myo-inositol, uric acid, and tryptophan showing the maximum combined classification performance. Metabolic pathways including energy metabolism, antioxidant defense systems, neurotransmitter metabolism, fatty acid biosynthesis, and phospholipid metabolism were found to be disturbed in schizophrenic patients and partially normalized following risperidone therapy. Further study of these metabolites may facilitate the development of noninvasive biomarkers and more efficient therapeutic strategies for schizophrenia.

KW - atypical antipsychotics

KW - gas chromatography-mass spectrometry

KW - metabolomics

KW - potential biomarkers

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=82755181967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755181967&partnerID=8YFLogxK

U2 - 10.1021/pr2006796

DO - 10.1021/pr2006796

M3 - Article

C2 - 22007635

AN - SCOPUS:82755181967

VL - 10

SP - 5433

EP - 5443

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 12

ER -